Navigation Links
CardioGenics Announces Reverse Stock Split
Date:6/18/2010

MISSISSAUGA, Ontario, June 18 /PRNewswire-FirstCall/ -- CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), developer of the ultra-sensitive QL Care™ Point-Of-Care (POC) analyzer and products for the immunoassay segment of the In-Vitro Diagnostics market, announced today that the Company has filed a Certificate of Change with the Secretary of State of Nevada, which implements a share consolidation of the Company's authorized and outstanding common stock on a ten (old) for one (new) basis.

FINRA has completed its review of the share consolidation of CardioGenics Holdings Inc. and, based on discussions with FINRA, the Company anticipates that the share consolidation will be effective in the market commencing Monday, June 21st. The post-consolidation common stock, which currently trades on the OTCBB, has a new CUSIP number and will be assigned a new ticker symbol by FINRA. The new CUSIP number is 14160X 203. Stockholders do not need to take any action in connection with the share consolidation. If you hold shares of the Company's common stock in "street name" through a broker, bank or other financial institution your shares will be automatically adjusted in accordance with the share consolidation ratio. If you hold shares of the Company's common stock in certificate or registered form, the Company's transfer agent will, likewise, adjust your holdings in accordance with the share consolidation ratio.

As a result of the share consolidation, the Company now has 65,000,000 authorized shares of common stock, of which 24,682,250 common shares are currently outstanding. In addition, the "Exchangeable Shares" of CardioGenics ExchangeCo Inc., the Company's Canadian subsidiary, which are exchangeable at any time into the Company's common stock are also in the process
'/>"/>

SOURCE CardioGenics Holdings Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. CardioGenics Announces Update Regarding Status of Merck Agreement
2. CardioGenics to be Spotlighted in Three Publications During Month of April
3. CardioGenics Announces Lock-Up Agreement with Dr. Yahia Gawad
4. CardioGenics Announces Further Update Regarding Status of Merck Agreement
5. CardioGenics Announces Completion of Cartridge Design for QL Care Analyzer
6. Dr. Yahia Gawad, CEO of CardioGenics Holdings, Inc., Interviewed in MedTech Executive
7. CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads
8. CardioGenics Holdings Inc. Featured in Medical Device Daily
9. CardioGenics Holdings Inc. Announces Letter to Shareholders
10. CardioGenics Holdings Inc. Provides Update on FINRA Submission Regarding Name Change
11. K-V Pharmaceutical Company Announces the Nomination and Appointment of New Independent Member to the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... --  Nektar Therapeutics (Nasdaq: NKTR ) today ... study for NKTR-181, a first-in-class, opioid analgesic molecule ... slow rate of entry is designed to reduce the euphoria ... current opioid analgesics. 1 In the study data being ... in "drug liking" and "feeling high" scores and had highly ...
(Date:6/19/2013)... 2013 BD Biosciences, a segment of BD (Becton, ... global medical technology company, today announced the launch of the ... its line of high-performance research flow cytometers. ... with the most compact footprint in its class at just ... of 30" (76.2 cm). Recognizing that space is a valuable ...
(Date:6/19/2013)... ZIONA, Israel , June ... announced that results from a phase I study in ... in advanced Parkinson,s patients, of ND0612, were presented at ... Disorders. ND0612 is a proprietary levodopa/carbidopa liquid drug formula ... delivery patch that would maintain constant levodopa plasma concentrations. ...
Breaking Medicine Technology:Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6
... treated with,Exforge achieved recommended blood pressure goals[1] , ... observed in patients taking Exforge over,reductions seen with previous ... blood pressure not,at treatment target levels[2] and most require ... , BASEL, Switzerland, May 21, 2007 ...
... by FDA for long-term maintenance,treatment of COPD ... improved lung function,comparable to dry powder formoterol, ... profile --, NAPA, Calif., May 20, 2007 ... of the American Thoracic Society (ATS),demonstrate that ...
Cached Medicine Technology:Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 2Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 3Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 4Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 5Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 6Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 7Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 8Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 2Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 3Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 4Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 5Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 6Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 7
(Date:6/19/2013)... Chrysler made news recently when it refused ... million Jeeps. The Jeep models in question are the 1993-2004 ... to the NHTSA are vulnerable to fire and explosion in ... are rear-mounted and have been alleged to catch fire or ... Cherokee with 32 rear-end crashes, which resulted in 44 deaths ...
(Date:6/19/2013)... CA (PRWEB) June 19, 2013 According to ... for Surviving Weekend Sunburn,” it is not uncommon for a ... the summer months. A person is likely to forget to ... , which is both dry and itchy. When this occurs, ... (Go to goo.gl/gDyjP). , “Most people do not realize that ...
(Date:6/19/2013)... a study published in the June 19 online edition ... led by researchers from the University of California, San ... events that take place when cardiac regeneration occurs in ... evidence that various cell lines in the heart are ... types, than previously thought. , More importantly, the research ...
(Date:6/19/2013)... This news release is available in Spanish . ... the field of neglected diseases, it goes by the name ... health research was devoted to conditions that accounted for 90 ... counteract this imbalance that the Drugs for Neglected Diseases initiative ... anniversary year, the organization has been granted the BBVA Foundation ...
(Date:6/19/2013)... California (PRWEB) June 19, 2013 Effective Environmental ... launch of new websites. These online links are devoted to ... Septic Tank cleaner, Organic Odor Control Mold Magician and others. ... for fish and animals in the water as well as ... and sludge buildup that can accumulate at the bottom of ...
Breaking Medicine News(10 mins):Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 2Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 3Health News:Skin Care – How to treat Sunburn 2Health News:Fate of the heart: Researchers track cellular events leading to cardiac regeneration 2Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 2Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 3Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 4Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 5Health News:Effective Environmental Services Launch New Websites to Serve Customers 2
... A study by Henry Ford Hospital shows a direct association between ... shows that in most cases the rupture heals on its own ... "In the past, many otolaryngologists have wondered if surgery is really ... show that 97 percent of cases healed on their own within ...
... (HealthDay News) -- Memory in monkeys and humans is more ... with rhesus monkeys showed that, like people, they have both ... something when you see it. Recall is the ability to ... April 28 in the journal Current Biology . ...
... Behen HealthDay Reporter , THURSDAY, April 28 ... expand research and improve understanding of cancer among minority ... the President,s Cancer Panel. While minorities currently account ... expected to become the collective majority by the year ...
... Researchers have developed an effective technique that uses gene ... in cell culture, which could eventually serve as a treatment ... study published in Blood , the ... prevents neutrophils, a type of white blood cell of the ...
... in Germany compared with the rest of Europe. Extensive folic ... 85-100% of cases, Wolfgang Herrmann and Rima Obeid argue in ... Int 2011; 108[15]; 249-54). A woman,s folic acid intake ... not develop the neural tube defect commonly known as spina ...
... The largest study of its type has found that neither ... metformin, successfully reduced liver enzymes in nonalcoholic fatty liver disease ... the April 27, 2011 issue of Journal of the ... patients with a severe type of fatty liver disease, a ...
Cached Medicine News:Health News:Study: Cotton swabs prove problematic for ear health 2Health News:'Urgent Need' for Research on Cancer Among Minorities: U.S. Report 2Health News:'Urgent Need' for Research on Cancer Among Minorities: U.S. Report 3Health News:New gene therapy technique on iPS cells holds promise in treating immune system disease 2Health News:New gene therapy technique on iPS cells holds promise in treating immune system disease 3Health News:JAMA study reports on fatty liver disease in children and teens 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: